Entrada Therapeutics Inc
NASDAQ:TRDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
China Leadshine Technology Co Ltd
SZSE:002979
|
CN |
|
Ovzon AB (publ)
STO:OVZON
|
SE |
|
Trip.com Group Ltd
HKEX:9961
|
CN |
|
Cousins Properties Inc
NYSE:CUZ
|
US |
|
SMC Corp
TSE:6273
|
JP |
|
Daikaffil Chemicals India Ltd
BSE:530825
|
IN |
|
LG Electronics Inc
LSE:LGLD
|
KR |
|
Indigo Paints Ltd
NSE:INDIGOPNTS
|
IN |
|
Alfa Laval AB
OTC:ALFVF
|
SE |
|
China Haisum Engineering Co Ltd
SZSE:002116
|
CN |
|
Paris Miki Holdings Inc
TSE:7455
|
JP |
Entrada Therapeutics Inc
Total Receivables
Entrada Therapeutics Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Total Receivables
$1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$12.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$9.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$2.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Entrada Therapeutics Inc
Glance View
Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.
See Also
What is Entrada Therapeutics Inc's Total Receivables?
Total Receivables
1.2m
USD
Based on the financial report for Dec 31, 2025, Entrada Therapeutics Inc's Total Receivables amounts to 1.2m USD.
What is Entrada Therapeutics Inc's Total Receivables growth rate?
Total Receivables CAGR 1Y
-68%
Over the last year, the Total Receivables growth was -68%.
